Equities research analysts at StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV - Get Free Report) in a note issued to investors on Thursday. The firm set a "hold" rating on the biopharmaceutical company's stock.
MediciNova Trading Up 0.6 %
MediciNova stock traded up $0.01 during mid-day trading on Thursday, hitting $1.57. The company had a trading volume of 8,543 shares, compared to its average volume of 38,118. MediciNova has a 12-month low of $1.12 and a 12-month high of $2.16. The company has a market capitalization of $77.01 million, a price-to-earnings ratio of -9.81 and a beta of 0.77. The company's fifty day moving average is $1.81 and its 200-day moving average is $1.50.
MediciNova (NASDAQ:MNOV - Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. As a group, sell-side analysts expect that MediciNova will post -0.23 EPS for the current fiscal year.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
See Also
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
